1. Home
  2. GBIO vs GSIW Comparison

GBIO vs GSIW Comparison

Compare GBIO & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • GSIW
  • Stock Information
  • Founded
  • GBIO 2016
  • GSIW 2016
  • Country
  • GBIO United States
  • GSIW Hong Kong
  • Employees
  • GBIO N/A
  • GSIW N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • GSIW
  • Sector
  • GBIO Health Care
  • GSIW
  • Exchange
  • GBIO Nasdaq
  • GSIW Nasdaq
  • Market Cap
  • GBIO 29.2M
  • GSIW 27.2M
  • IPO Year
  • GBIO 2020
  • GSIW 2023
  • Fundamental
  • Price
  • GBIO $0.38
  • GSIW $1.46
  • Analyst Decision
  • GBIO Strong Buy
  • GSIW
  • Analyst Count
  • GBIO 4
  • GSIW 0
  • Target Price
  • GBIO $7.33
  • GSIW N/A
  • AVG Volume (30 Days)
  • GBIO 558.2K
  • GSIW 915.9K
  • Earning Date
  • GBIO 08-06-2025
  • GSIW 12-31-2024
  • Dividend Yield
  • GBIO N/A
  • GSIW N/A
  • EPS Growth
  • GBIO N/A
  • GSIW N/A
  • EPS
  • GBIO N/A
  • GSIW N/A
  • Revenue
  • GBIO $24,556,000.00
  • GSIW $1,313,795.00
  • Revenue This Year
  • GBIO N/A
  • GSIW N/A
  • Revenue Next Year
  • GBIO N/A
  • GSIW N/A
  • P/E Ratio
  • GBIO N/A
  • GSIW N/A
  • Revenue Growth
  • GBIO 146.47
  • GSIW N/A
  • 52 Week Low
  • GBIO $0.32
  • GSIW $0.35
  • 52 Week High
  • GBIO $3.65
  • GSIW $12.30
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 48.07
  • GSIW 77.10
  • Support Level
  • GBIO $0.35
  • GSIW $1.36
  • Resistance Level
  • GBIO $0.41
  • GSIW $1.78
  • Average True Range (ATR)
  • GBIO 0.03
  • GSIW 0.17
  • MACD
  • GBIO -0.00
  • GSIW 0.03
  • Stochastic Oscillator
  • GBIO 30.11
  • GSIW 69.52

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

Share on Social Networks: